Clinical trials
Alzheimer Disease or Associated Disorder clinical trials
Below are recruiting alzheimer disease or associated disorder clinical trials, each written for real people, not researchers. We’re tracking 1,816 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90 - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05231798RecruitingPhase 2
PET and brain scans in adults with Down syndrome
This study looks at how well a brain chemical system works in adults with Down syndrome as they age, including how it relates to Alzheimer’s-type brain changes and thinking skills. It uses brain scans and memory/thinking tests to see whether these measures can help track risk or changes over time.
Nashville, TennesseeAges 18–55 - NCT05322343Recruiting
Study biobank and brain health in people age 55–80
This study collects blood samples to build a biobank and learn how brain health changes with age. Some participants may also do an MRI scan to better understand brain changes and immune response.
Bordeaux, BordeauxAges 55–80 - NCT05417555Recruiting
Focused ultrasound for mild memory problems and early Alzheimer’s
This trial studies whether a low-intensity focused ultrasound treatment can improve brain function in people with mild cognitive impairment (early memory decline) or mild Alzheimer’s disease. It may help slow symptoms or improve how the brain works, but it’s still being tested.
Los Angeles, CaliforniaAges 50–90 - NCT05924425RecruitingPhase 4
Daridorexant for insomnia in early memory decline
This trial tests whether daridorexant can improve sleep in people who have mild cognitive impairment or early Alzheimer’s disease and struggle with insomnia. It may help by improving how long and how well you sleep, with monitoring of sleep patterns and memory-related measures.
MontpellierAges 60–85 - NCT06147999Recruiting
Biophoton therapy for brain disorders
This trial tests a biophoton therapy, a light-based treatment, for people with brain disorders. It aims to see if this non-invasive approach can help improve symptoms.
Butler, PennsylvaniaAges 18 years+ - NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases
This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.
Guangzhou, GuangdongAges 18–65 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06875986Recruiting
Study of REXULTI for agitation in Alzheimer's disease
This trial is studying how a medication called REXULTI works in patients with Alzheimer's disease who have symptoms like excessive activity, aggression, or mood swings. It aims to see if the drug helps manage these behaviors.
Osaka, OsakaAges 15 years+ - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT07435467Recruiting
Blood tests for brain health in older hospital patients
This trial looks at how blood biomarkers relate to thinking, daily function, and survival in older adults, including those with neurological issues or dementia. It aims to improve understanding and care for hospitalized seniors.
AnconaAges 65 years+ - NCT07595666Enrolling by invitation
New PET scanner versus standard PET for head and neck imaging
This study compares a newer PET/CT scanner (called NeuroEXPLORER) with standard PET/CT scanners for imaging the head and neck region. The goal is to see if the new scanner provides better or clearer images to help diagnose conditions.
Leuven, Vlaams-BrabantAges 4 weeks+ - NCT07233512Enrolling by invitation
Periodontal treatment for Alzheimer's disease
This trial tests whether treating gum disease can improve outcomes for people with Alzheimer's disease. If you have mild to moderate Alzheimer's and gum disease, you may be able to join.
LiègeAges Any age - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT03233646Recruiting
Retina scans in memory and nerve disorders
This study uses pictures of the back of your eye (retinal imaging) to look for differences in people with neurodegenerative diseases and compares them with people without these conditions. It may help researchers understand eye changes that could connect to brain or nerve health.
Durham, North CarolinaAges 18 years+ - NCT06596746Recruiting
Tracking markers for neurodegenerative diseases
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
Cassino, FrosinoneAges 10 years+ - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+
Hear when a new Alzheimer Disease or Associated Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer disease or associated disorder?
- Yes. Clin2 currently lists 1,816 recruiting alzheimer disease or associated disorder studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer disease or associated disorder trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer disease or associated disorder trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.